Axogen Inc Stock Price, News & Analysis

Axogen, a leader in surgical solutions for peripheral nerve damage, will participate in the 76th Annual Meeting of the American Society for Surgery of the Hand (ASSH) from September 30-October 2, 2021 in San Francisco. The company will host a symposium on October 1, featuring an expert panel discussing the impact of Axogen technologies on nerve repair practices. Attendees can engage with Axogen scientists and explore innovative surgical techniques at Booth #950. Axogen will also support educational initiatives and offer travel scholarships for attendees.

Axogen announced the completion of subject follow-up for its pivotal RECON Clinical Study, supporting the Biologics License Application (BLA) for Avance® Nerve Graft. The study met its enrollment target of 220 subjects in July 2020 and is on track for a top-line data read-out in Q2 2022, followed by BLA submission in 2023. The RECON study aims to provide Level 1 clinical data, comparing Avance Nerve Graft to manufactured conduits in digital nerve injuries, focusing on recovery of sensation and quality of life outcomes.

Axogen, Inc. (NASDAQ: AXGN) reported a strong second quarter for 2021, with net revenue of $33.6 million, a 52% increase year-over-year. The company achieved a gross margin of 78.9%, boosted by a recovery in sales despite a $1.4 million one-time charge. While the net loss was $7.9 million ($0.19 per share), this showed improvement compared to the prior year. Additionally, Axogen updated its 2021 revenue guidance to a range of $134.5 million to $137.5 million, enhancing investor confidence in long-term growth.

Axogen, Inc. (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerves, announced that CEO Karen Zaderej will present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 1:00 p.m. ET. The event will be available for live streaming on Axogen’s Investors page, with a replay accessible for 90 days. Axogen specializes in technologies for nerve regeneration and repair, offering products like Avance® Nerve Graft and Axoguard Nerve Connector® to restore peripheral nerve function, crucial after injuries or surgeries affecting the nervous system.

Axogen, Inc. (NASDAQ: AXGN) has appointed John H. Johnson to its Board of Directors as of July 19, 2021. Johnson brings over 30 years of biopharma experience from senior roles at major companies including Johnson & Johnson and Eli Lilly. He will contribute to both the Governance, Nominating and Sustainability Committee and the Science and Technology Committee. CEO Karen Zaderej highlights Johnson's expertise in pipeline strategy and commercial execution as a significant asset for the company’s ongoing commitment to innovation in peripheral nerve repair.

Axogen, Inc. (NASDAQ: AXGN) announced it will report Q2 2021 financial results on August 4, 2021, after market close. Management will host a conference call at 4:30 p.m. ET. Interested investors can participate via phone or listen online through Axogen's website. The company specializes in surgical solutions for peripheral nerve repair, offering products like Avance Nerve Graft and Axoguard Nerve Connector. Axogen aims to improve patient outcomes following peripheral nerve injuries.

Axogen, Inc. (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerve damage, announced presentations by CEO Karen Zaderej and CFO Peter Mariani at two investor conferences. They will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 11:30 a.m. ET, and the JMP Securities Life Sciences Conference on June 16, 2021, at 12:30 p.m. ET. Both events will be webcast live, with replays available on the Axogen Investors page for 90 days. Axogen focuses on the development and commercialization of technologies for peripheral nerve regeneration.

Axogen, a leader in surgical solutions for peripheral nerve repair, announced that Peter J. Mariani, CFO, will present at the Canaccord Genuity Musculoskeletal Conference on May 20, 2021, at 11:00 a.m. ET. The presentation will be accessible via live webcast on the company’s investor page. Axogen specializes in technologies that aid in the regeneration and repair of peripheral nerves, aiming to restore nerve function and quality of life for patients affected by nerve damage. Its product portfolio includes several innovative solutions such as Avance® Nerve Graft and Axoguard series.

Axogen, Inc. (NASDAQ: AXGN) reported a 28% increase in net revenue for Q1 2021, totaling $31.0 million compared to $24.3 million in Q1 2020. The gross margin improved to 83.3% from 80.1% year-over-year. Despite a net loss of $6.7 million or $0.16 per share, this was an improvement over the previous year’s loss of $8.2 million. The company ended Q1 2021 with $97.2 million in cash and investments. Axogen anticipates full-year 2021 revenue to be between $133 million and $136 million.